AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Lifecare ASA Capital/Financing Update 2024

May 29, 2024

3654_rns_2024-05-29_fd2bec91-7531-448c-aa13-a4106ec7b695.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

LIFECARE ASA: FAQ REGARDING RIGHTS ISSUE

Reference is made to the previous stock exchange announcements published by Lifecare ASA ("Lifecare" or the "Company") regarding the partially underwritten rights issue.

Frequently asked questions (FAQ) on the Rights Issue is avalaible in the attachment.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

Attachments